medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2009, Número 3

<< Anterior Siguiente >>

Rev Inst Nal Enf Resp Mex 2009; 22 (3)


Avances recientes en el conocimiento fisiopatológico de la fibrosis pulmonar idiopática

Vega MA, Ruiz LVM

Idioma: Español
Referencias bibliográficas: 55
Paginas: 190-197
Archivo PDF: 82.79 Kb.


RESUMEN

La comprensión de los mecanismos moleculares relacionados con la fibrosis pulmonar idiopática (FPI) se ha acelerado considerablemente en la última década. La aplicación de diversas metodologías clásicas de bioquímica, biología molecular y genética ha sido clave para la comprensión de la fisiopatología de la FPI, una muestra de esto es el descubrimiento del papel de la telomerasa en la enfermedad y del reclutamiento de fibroblastos en el desarrollo de la misma. Por el contrario, las tecnologías de microarreglos y proteómica todavía tienen un poder de interpretación muy limitado. En el futuro, seremos testigos de avances considerables en la forma de interpretar los datos obtenidos por estas dos metodologías, permitiendo entender los mecanismos, los tratamientos y los eventuales procesos de esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.

  2. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-594.

  3. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417.

  4. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827.

  5. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-422.

  6. Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 2005;11:3943-3971.

  7. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.

  8. Kaminski N. Microarray analysis of idiopathics pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:S32-S36.

  9. Kaminski N, Rosas IO. Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes? Proc Am Thorac Soc 2006;3:339-344.

  10. Tzouvelekis A, Harokopos V, Paparountas T, et ál. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med 2007;176:1108-1119.

  11. Tzouvelekis A, Aidinis V, Harokopos V, et ál. Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respir Res 2009;10:14.

  12. Lewis CC, Yang JY, Huang X, et ál. Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med 2008;177:376-387.

  13. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-1901.

  14. Montuschi P, Ciabattoni G, Paredi P, et ál. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998;158(5 Pt 1):1524-1527.

  15. Psathakis K, Mermigkis D, Papatheodorou G, et ál. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur J Clin Invest 2006;36: 362-367.

  16. Kabuyama Y, Oshima K, Kitamura T, et ál. Involvement of selenoprotein P in the regulation of redox balance and myofibroblast viability in idiopathic pulmonary fibrosis. Genes Cells 2007;12:1235-1244.

  17. Boon K, Bailey NW, Yang J, et ál. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 2009;4:e5134.

  18. Rottoli P, Magi B, Perari MG, et ál. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:1423-1430.

  19. Rottoli P, Magi B, Cianti R, et ál. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5: 2612-2618.

  20. Rosas IO, Richards TJ, Konishi K, et ál. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.

  21. Vuorinen K, Myllarniemi M, Lammi L, et ál. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS 2007;115:969-975.

  22. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzún M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;163:1648-1653.

  23. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006;7:55-65.

  24. Ioannidis JP, Allison DB, Ball CA, et ál. Repeatability of published microarray gene expression analyses. Nat Genet 2009;41:149-155.

  25. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525.

  26. Raghu G, Weycker D, Edelsberg J, Bradfort WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816.

  27. Marshall RP, Puddicombe A, Cookson WO, Laurent CJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000;55:143-146.

  28. Tsakiri KD, Cronkhite JT, Kuan PJ, et ál. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007;104:7552-7557.

  29. Armanios MY, Chen JJ, Cogan JD, et ál. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317-1326.

  30. Alder JK, Chen JJ, Lancaster L, et ál. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008;105:13051-13056.

  31. Tager AM, LaCamera P, Shea BS, et ál. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54.

  32. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106.

  33. Drab M, Verkade P, Elger M, et ál. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293:2449-2452.

  34. Wang XM, Zhang Y, Kim HP, et ál. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006;203:2895-2906.

  35. Tourkina E, Richard M, Gööz P, et ál. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008;294: L843-L861.

  36. Eferl R, Hasselblatt P, Rath M, et ál. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A 2008;105:10525-10530.

  37. Pardo A, Gibson K, Cisneros J, et ál. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005;2:e251.

  38. Collard HR, Ryu JH. Douglas WW, et ál. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004;125:2169-2174.

  39. Raghu G, Depaso WJ, Cain K, et ál. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-296.

  40. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-288.

  41. Zisman DA, Lynch JP 3rd, Toews GB, Kaserooni EA, Flint A, Martinez FJ. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: A prospective study in patients who failed to respond to corticosteroids. Chest 2000;117:1619-1626.

  42. Demedts M, Behr J, Buhl R, et ál. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-2242.

  43. Douglas WW, Ryu JH, Swensen SJ, et ál. Colchicine versus prednisone in the treatment of idiophatic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998;158:220-225.

  44. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161:1172-1178.

  45. Selman M, Carrillo G, Salas J, et ál. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: A controlled Clinical trial. Chest 1998;114:507-512.

  46. Regulatory watch: First drug for idiopathic pulmonary fibrosis approved in Japan. Nat Rev Drug Discov 2008;7:966-967.

  47. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am J Respir Crit Care Med 1999;160:1771-1777.

  48. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-218.

  49. Shi-wen X, Kennedy L, Renzoni EA, et ál. Endothelin is a down-stream mediator of profibrotic responses to transforming grown factor beta in human lung fibroblasts. Arthritis Rheum 2007;56:4189-4194.

  50. Park SH, Saleh D, Giaid A, et ál. Increased endothelin-1 in bleomycin -induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:600-608.

  51. Raghu G, Brown KK, Costabel U, et ál. Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-955.

  52. Raghu G, Brown KK, Bradford WZ, et ál. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133.

  53. King TE Jr, Safrin S, Starko KM, et ál. Analyses of efficacy end points in a controlled trial of interferon -gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-177.

  54. King TE Jr, Albera C, Bradford WZ, et ál. The effect of interferon gamma1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomized, placebo-controlled trial. Lancet 2009;374:222-228.

  55. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.




2020     |     www.medigraphic.com